on GENOWAY (EPA:ALGEN)
Genoway anticipates dynamic growth in 2026
Genoway, a specialist in predictive preclinical solutions, announces revenue of €21 million for 2025, a 5% decrease compared to 2024, in a cautious economic environment. The company anticipates organic growth of 10% in 2026, driven by its revamped sales structure.
2025 was marked by a strategic overhaul, including new hires and a new marketing plan. Significant cost savings were achieved, offsetting increased investments. Genoway also acquired data science/AI assets, accelerating its ROUTE50+DATA strategic plan.
The company intends to increase its international presence, particularly in Asia. It aims for a turnover of €23 million in 2026, with a target of €50 million by 2028, while maintaining EBITDA margins above 15%.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news